title: Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications.
abstract: OBJECTIVE
  We conduct a critical evaluation of cryoablation of prostate cancer after failure of full dose radiotherapy to identify predictors of treatment failure and complications.
  
  
  METHODS
  A total of 125 cryoablation procedures were performed in 118 patients with proved local recurrence after full dose radiotherapy. Followup includes serial prostate specific antigen (PSA) and biopsy at 6,12 and 24 months. Kaplan-Meier plots were constructed for different PSA cutoffs. We separately analyzed different cohorts based on T stage, Gleason score, PSA before cryoablation and endocrine therapy status.
  
  
  RESULTS
  Of the 118 patients 114 had serum PSA nadir less than 0.5 ng./ml. Median followup was 18.6 months (range 3 to 54). Of the biopsy cores 3.1% (23 of 745) from 7 patients contained persistent viable cancer. Kaplan-Meier plots showed patients free of histological failure leveling at 87% and free from biochemical failure at 68%, 55% and 34%, respectively, with PSA greater than 4, 2 and 0.5 ng./ml. PSA greater than 10 ng./ml. before cryoablation, Gleason score 8 or greater before radiation and stage T3/T4 disease appeared to predict an unfavorable biochemical outcome. Serious complications included 4 rectourethral fistulas (3.3%) and severe incontinence (6.7%). Strong predictors of complications included bulky disease for fistulas and prior transurethral surgery.
  
  
  CONCLUSIONS
  Salvage cryoablation after radiation can achieve reasonable biochemical and histological results with acceptable morbidity. Cryoablation appears to be a reasonable treatment option for this patient population with few viable therapeutic options, provided vigorous patient selection criteria are adhered to.
authors.affiliation: Division Of Urology and Department Of Diagnostic Radiology, London Health Sciences Centre, University Of Western Ontario, London, Ontario, Canada.
authors.forename: J L
authors.initials: JL
authors.lastname: Chin
authors.forename: S E
authors.initials: SE
authors.lastname: Pautler
authors.forename: V
authors.initials: V
authors.lastname: Mouraviev
authors.forename: N
authors.initials: N
authors.lastname: Touma
authors.forename: K
authors.initials: K
authors.lastname: Moore
authors.forename: D B
authors.initials: DB
authors.lastname: Downey
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D003452:Cryosurgery; D006801:Humans; D008297:Male; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D017211:Treatment Failure
chemical_list: D017430:Prostate-Specific Antigen